期刊
ONCOGENE
卷 37, 期 12, 页码 1561-1575出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41388-017-0045-7
关键词
-
资金
- Alex's Lemonade Stand Foundation
- Program for Breakthrough Biomedical Research - Sandler Foundation
- NIH [CA148699, NS091620, NS0883555, NS089868, CA183692, CA176287, CA82103]
- Children's Tumor Foundation
- Katie Dougherty Foundation
- Pediatric Brain Tumor Foundation
- Ross K. MacNeill Foundation
- St. Baldrick Foundation
- Samuel G. Waxman Foundation
- Evelyn and Mattie Anderson Chair
Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据